YM 31758
Latest Information Update: 09 Aug 2002
Price :
$50 *
At a glance
- Originator Yamanouchi
- Class
- Mechanism of Action Cholestenone 5 alpha-reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Benign prostatic hyperplasia
Most Recent Events
- 11 Feb 2000 New profile
- 11 Feb 2000 Preclinical development for Benign prostatic hyperplasia in Japan (Unknown route)